Heron Therapeutics (HRTX) Net Cash Flow (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Net Cash Flow came in at -$2.5 million in Q1 2026, up 61.27% YoY from -$1.6 million in Q1 2025, and up 82.46% on a QoQ basis from -$14.4 million in Q4 2025.
Heron Therapeutics (HRTX) Net Cash Flow (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Net Cash Flow data on file, last reported at -$2.5 million in Q1 2026.
- Quarterly Net Cash Flow rose 61.27% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 679.85% YoY) and the FY2025 annual result came in at $2.8 million, up 198.96% from the prior year.
- Net Cash Flow rose to -$2.5 million in Q1 2026, from -$14.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $26.6 million in Q3 2025 to a low of -$35.1 million in Q4 2022.
- A 5-year average of -$3.8 million and a median of -$2.8 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 1069.87% — and 2025, when it tumbled 23740.98%.
- Tracing HRTX's Net Cash Flow over 5 years: stood at -$35.1 million in 2022, then soared by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61000.0 in 2024, then plunged by 23740.98% to -$14.4 million in 2025, then soared by 82.46% to -$2.5 million in 2026.
- The last three Net Cash Flow figures came in at -$2.5 million (Q1 2026), -$14.4 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.40 Mn |
| Jun 30, 2026 | -5.40 Mn |
| Mar 31, 2026 | -2.53 Mn |
| Mar 31, 2026 | -2.53 Mn |
| Dec 31, 2025 | -14.42 Mn |
| Dec 31, 2025 | -14.42 Mn |
| Sep 30, 2025 | 26.55 Mn |
| Sep 30, 2025 | 26.55 Mn |
| Jun 30, 2025 | -2.75 Mn |
| Jun 30, 2025 | -2.75 Mn |
| Mar 31, 2025 | -6.53 Mn |
| Mar 31, 2025 | -6.53 Mn |
| Dec 31, 2024 | 61,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 7.36 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Jun 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -2.06 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Mar 31, 2024 | -8.23 Mn |